Skip to main content

Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis

Journal of Thrombosis and Thrombolysis volume 52, pages 1084–1093 (2021)Cite this article

Abstract

Studies on the association of uric acid with mortality and cardiovascular outcomes in patients with hypertension have produced contradictory results. The objective of this meta-analysis was to evaluate the prognostic utility of uric acid in hypertensive patients. We comprehensively searched PubMed and Embase databases (until July 31, 2020) to identify eligible studies that reported the association of uric acid with mortality and cardiovascular outcomes in hypertensive patients. Outcome measures included cardiovascular or all-cause mortality, coronary artery disease (CAD), stroke, and major adverse cardiovascular events (MACEs). Eleven eligible studies of 49,800 hypertensive patients were identified. For patients with the highest than those with reference lower group of uric acid level, the pooled hazard ratio (HR) was 1.51 (95% confidence interval [CI] 1.12–2.02) for all-cause mortality, 1.68 (95% CI 1.28–2.20) for cardiovascular mortality, 1.31 (95% CI 1.10–1.55) for CAD, and 1.48 (95% CI 1.28–1.70) for MACEs. However, there was no significant association between elevated uric acid level and incident stroke in hypertensive patients. This meta-analysis indicates that elevated uric acid level is significantly associated with an increased risk of cardiovascular or all-cause mortality, CAD and MACEs in hypertensive patients. Hypertensive patients with highest uric acid level exhibited a tendency for reduced risk of stroke, but the difference is not significant.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, Li J (2014) Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS ONE 9(12):e114259

    Article  Google Scholar 

  2. Buzas R, Tautu OF, Dorobantu M, Ivan V, Lighezan D (2018) Serum uric acid and arterial hypertension-Data from Sephar III survey. PLoS ONE 13(7):e0199865

    Article  Google Scholar 

  3. Zhao G, Huang L, Song M, Song Y (2013) Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 231(1):61–68

    CAS  Article  Google Scholar 

  4. Yue M, Zhang H, Li R (2016) Meta-analysis on the risk of all-cause mortality and cardiovascular death in the early stage of hypertension. Pak J Pharm Sci 29(4 Suppl):1343–1351

    PubMed  Google Scholar 

  5. Khoury SR, Ratchford EV (2018) Hypertension. Vasc Med 23(3):293–297

    Article  Google Scholar 

  6. Alderman MH, Cohen H, Madhavan S, Kivlighn S (1999) Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34(1):144–150

    CAS  Article  Google Scholar 

  7. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P (2000) Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36(6):1072–1078

    CAS  Article  Google Scholar 

  8. Turak O, Afsar B, Ozcan F, Canpolat U, Grbovic E, Mendi MA, Oksuz F, Siriopol D, Covic A, Caliskan M, McFann K, Johnson RJ, Kanbay M (2014) Relationship between elevated morning blood pressure surge, uric acid, and cardiovascular outcomes in hypertensive patients. J Clin Hypertens (Greenwich) 16(7):530–535

    CAS  Article  Google Scholar 

  9. Wang J, Wang Y, Zhao D, Guo X, Zhong JQ (2015) Association between serum uric acid and mortality in a Chinese population of hypertensive patients. Ren Fail 37(1):73–76

    Article  Google Scholar 

  10. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB (2000) Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 18(8):1149–1154

    CAS  Article  Google Scholar 

  11. Kawai T, Ohishi M, Takeya Y, Onishi M, Ito N, Yamamoto K, Kamide K, Rakugi H (2012) Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients. Hypertens Res 35(11):1087–1092

    CAS  Article  Google Scholar 

  12. Dawson J, Jeemon P, Hetherington L, Judd C, Hastie C, Schulz C, Sloan W, Muir S, Jardine A, McInnes G, Morrison D, Dominiczak AF, Padmanabhan S, Walters M (2013) Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients. Hypertension 62(1):105–111

    CAS  Article  Google Scholar 

  13. Shi X, Yang J, Wang L, Zhao M, Zhang C, He M, Qin X, Tang G, Li J, Zhang Y, Huo Y, Cai Y, Zhao G, Dong Q, Xu X, Wang B, Fu J, Wang K (2017) Prospective study of serum uric acid levels and stroke in a Chinese hypertensive cohort. Clin Exp Hypertens 39(6):527–531

    CAS  Article  Google Scholar 

  14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1-34

    Article  Google Scholar 

  15. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2020) The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Assessed 28 Aug 2020

  16. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101

    CAS  Article  Google Scholar 

  17. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    CAS  Article  Google Scholar 

  18. Andrikou I, Tsioufis C, Dimitriadis K, Konstantinidis D, Kasiakogias A, Kouremeti M, Andrikou E, Karapati I, Kalos T, Fragoulis C, Liatakis I, Koutra E, Kyriazopoulos K, Thomopoulos C, Tousoulis D (2018) Uric acid as an independent predictor of coronary artery disease in essential hypertension: data from an 8-year-follow-up study. Clin Exp Pharmacol Physiol 45(8):866–869

    CAS  Article  Google Scholar 

  19. Gu J, Fan YQ, Zhang HL, Zhang JF, Wang CQ (2018) Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. J Clin Hypertens (Greenwich) 20(3):560–567

    CAS  Article  Google Scholar 

  20. Sun SS, Cai Y, Xu WH, Huang X, Yang WY, Luo JK, Ma YF, Cai J (2020) Effect of asymptomatic hyperuricemia on all-cause death and cardiovascular events in elderly hypertensive patients. Chin J Geriatr Heart Brain Vessel Dis 22(4):368–371

    Google Scholar 

  21. Huang G, Qin J, Deng X, Luo G, Yu D, Zhang M, Zhou S, Wang L (2019) Prognostic value of serum uric acid in patients with acute heart failure: a meta-analysis. Medicine (Baltimore) 98(8):e14525

    CAS  Article  Google Scholar 

  22. Wang R, Song Y, Yan Y, Ding Z (2016) Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis. Atherosclerosis 254:193–199

    CAS  Article  Google Scholar 

  23. Xia X, Luo Q, Li B, Lin Z, Yu X, Huang F (2016) Serum uric acid and mortality in chronic kidney disease: a systematic review and meta-analysis. Metabolism 65(9):1326–1341

    CAS  Article  Google Scholar 

  24. Perticone M, Tripepi G, Maio R, Cimellaro A, Addesi D, Baggetta R, Sciacqua A, Sesti G, Perticone F (2017) Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension. Int J Cardiol 243:473–478

    Article  Google Scholar 

  25. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L (2001) Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 37(4):1069–1074

    CAS  Article  Google Scholar 

  26. Tsioufis C, Kyvelou S, Dimitriadis K, Syrseloudis D, Sideris S, Skiadas I, Katsi V, Stefanadi E, Lalos S, Mihas C, Poulakis M, Stefanadis C (2011) The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. J Hum Hypertens 25(9):554–559

    CAS  Article  Google Scholar 

  27. Esen AM, Akcakoyun M, Esen O, Acar G, Emiroglu Y, Pala S, Kargin R, Karapinar H, Ozcan O, Barutcu I (2011) Uric acid as a marker of oxidative stress in dilatation of the ascending aorta. Am J Hypertens 24(2):149–154

    CAS  Article  Google Scholar 

  28. Zapolski T, Wacinski P, Kondracki B, Rychta E, Buraczynska MJ, Wysokinski A (2011) Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiol Pol 69(4):319–326

    PubMed  Google Scholar 

  29. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F (2006) Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 17(5):1466–1471

    CAS  Article  Google Scholar 

  30. Tsioufis C, Chatzis D, Vezali E, Dimitriadis K, Antoniadis D, Zervoudaki A, Lalos S, Kallikazaros I, Stefanadis C, Toutouzas P (2005) The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens 19(3):211–217

    CAS  Article  Google Scholar 

  31. Fan Y, Wei F, Lang Y, Wang S (2015) Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. J Hypertens 33(4):681–688 (discussion 689)

    CAS  Article  Google Scholar 

  32. Tykarski A, Widecka K, Filipiak KJ (2015) Zasady postępowania w nadciśnieniu tętniczym—2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Próba komentarza na temat ich zasadności. Nadciśnienie Tętnicze w Praktyce 1(1):71–79

    Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Cardiology, The Third Medical Center of PLA General Hospital, No. 69 Yongding Road, Haidian District, Beijing, 100039, China

    Yong Yang, Zhigeng Jin & Qing Zhao

  2. Medical Service Department, The Third medical center of PLA General Hospital, Beijing, 100039, China

    Xuyi Zhang

Authors
  1. Yong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuyi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhigeng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong Yang.

Ethics declarations

Conflict of interest

None of the authors have relevant conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yang, Y., Zhang, X., Jin, Z. et al. Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis. J Thromb Thrombolysis 52, 1084–1093 (2021). https://doi.org/10.1007/s11239-021-02453-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-021-02453-z

Keywords

  • Uric acid
  • Mortality
  • Major adverse cardiovascular events
  • Hypertension
  • Stroke
  • Meta-analysis